Form 6-K TEVA PHARMACEUTICAL INDU For: Nov 15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Teva Pharma (TEVA) Tops Q3 EPS by 2c; Offers Q4 Outlook
November 15, 2016 7:01 AM EST(Updated - November 15, 2016 7:05 AM EST)
Teva Pharma (NYSE: TEVA) reported Q3 EPS of $1.31, $0.02 better than the analyst estimate of $1.29. Revenue for the quarter came in at $5.56 billion versus the consensus estimate of $5.75 billion.
The company sees Q3 EPS of $1.34 - $1.44 with... More
